MIPLYFFA Data Shows Long-Term Hope for Niemann-Pick Patients

CELEBRATION, FL – February 04, 2026 – New, long-term data on Zevra Therapeutics' drug MIPLYFFA® (arimoclomol) is offering a significant beacon of hope for patients with Niemann-Pick disease Type C (NPC), a rare and fatal neurodegenerative disorder often called "Childhood Alzheimer's." The company presented four years of compelling real-world evidence at the 22nd Annual WORLDSymposium™, a premier scientific conference focused on lysosomal diseases.

The findings demonstrate that MIPLYFFA can meaningfully stabilize disease progression, a crucial outcome for a condition characterized by relentless decline. This announcement reinforces the drug's clinical value just months after its landmark U.S. approval and provides the most robust insights to date on its long-term impact, particularly in an understudied adult patient population.

A New Era of Evidence

The data, gathered from the U.S. Early Access Program (EAP), paints a picture of sustained benefit and tolerability. A key presentation highlighted that over a four-year period, patients treated with arimoclomol showed disease stabilization, with clinical severity scores remaining below the threshold for what is considered clinically meaningful worsening. This suggests the drug is not just offering a temporary reprieve but a durable, long-term effect.

“These data highlight MIPLYFFA’s potential to meaningfully stabilize disease progression across a broad spectrum of NPC patients, including adults who have historically had limited clinical data,” said Adrian Quartel, M.D., FFPM, Zevra’s Chief Medical Officer, in the company's press release. “As controlled clinical trial results are reinforced by long-term real-world experience, we continue to strengthen our understanding of MIPLYFFA’s impact."

Another analysis presented showed that when combined with the existing therapy miglustat, arimoclomol demonstrated a statistically significant slowing of disease progression as early as three months after starting treatment, with the benefit increasing over the course of a year. This rapid onset of action is a critical finding for families desperate to halt the disease's devastating effects on ambulation, speech, swallowing, and fine motor skills.

Perhaps most significantly, the new dataset provides the first published evidence on arimoclomol's impact specifically in adult NPC patients. For years, this group has been largely overlooked in clinical research. The four-year data confirms that adults also experienced disease stabilization with a favorable safety profile, validating the treatment's utility across the entire patient lifespan.

From Clinical Trial to Real-World Impact

The journey of MIPLYFFA to patients has been a story of perseverance, not only for Zevra Therapeutics but also for the patient advocacy community. The drug received its long-awaited approval from the U.S. Food and Drug Administration (FDA) on September 20, 2024, becoming one of the first-ever approved treatments for the neurological manifestations of NPC in the United States. Its indication for use is in combination with miglustat for patients two years of age and older.

The approval was a monumental milestone for the NPC community, which had actively campaigned for access, even submitting an informal petition to the FDA highlighting the urgent unmet need. The real-world data presented this week is a powerful validation of that advocacy. It demonstrates how Early Access Programs can bridge the gap between the controlled environment of a clinical trial and the complexities of everyday medical practice, providing crucial insights into a drug's long-term performance.

For rare diseases like NPC, where patient populations are small and geographically dispersed, generating such longitudinal data is both challenging and essential. The more than five years of patient experience collected across over 270 individuals worldwide—through clinical trials, extension studies, and the EAP—represents one of the most expansive clinical development programs ever undertaken for Niemann-Pick disease Type C.

Navigating a New Treatment Landscape

The approval of MIPLYFFA heralded a new era for NPC treatment, but it did not happen in a vacuum. In a remarkable turn of events for the rare disease community, another therapy, AQNEURSA (levacetylleucine), also received FDA approval for NPC in the same month. After decades with no approved options, patients and clinicians suddenly found themselves with two new therapies, creating a novel competitive and clinical landscape.

For Zevra, the robust, long-term data presented at WORLDSymposium™ serves to fortify MIPLYFFA's position in the market. By demonstrating sustained efficacy and safety over four years, the company provides clinicians with added confidence for long-term prescribing. This evidence is crucial as Zevra looks to expand its reach beyond the U.S. The company has already submitted a Marketing Authorization Application to the European Medicines Agency (EMA), seeking to bring arimoclomol to patients in Europe, where it has already received an Orphan Medicinal Product designation.

The commercial-stage company is leveraging the success of MIPLYFFA to build its foundation in the rare disease space, guided by a strategy that aims to combine scientific rigor with a deep understanding of patient needs. The new data not only strengthens the case for MIPLYFFA but also underscores the company's commitment to generating the evidence necessary to support its therapies long after initial approval.

The Science of Stabilization and Safety

MIPLYFFA works by increasing the activation of transcription factors that help regulate lysosomes, the cell's recycling centers, which are dysfunctional in NPC. While the full clinical significance of its mechanism is still being understood, the clinical outcomes are becoming clearer. The ability to halt disease progression, as measured by validated clinical scales, is a profound achievement.

Of course, no drug is without risks. The important safety information for MIPLYFFA notes the potential for hypersensitivity reactions, such as urticaria and angioedema, which were reported in a small number of patients during clinical trials. The drug can also cause an increase in serum creatinine that is not related to a change in kidney function, and physicians are advised to use alternative measures to assess renal health. The most common adverse reactions reported were upper respiratory tract infection, diarrhea, and decreased weight.

However, the four-year real-world data confirms that for the majority of patients, arimoclomol was well tolerated, maintaining a favorable safety profile over the long term. This balance of sustained efficacy and manageable safety is the cornerstone of a successful chronic therapy, and the latest findings provide a comprehensive look at how MIPLYFFA performs on both fronts, offering a clearer path forward for those living with Niemann-Pick disease Type C.